Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,147
Employees1,147
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,147
Employees1,147

EXEL Key Statistics

Market cap
11.17B
Market cap11.17B
Price-Earnings ratio
17.53
Price-Earnings ratio17.53
Dividend yield
Dividend yield
Average volume
3.18M
Average volume3.18M
High today
$42.59
High today$42.59
Low today
$39.50
Low today$39.50
Open price
$41.95
Open price$41.95
Volume
2.57M
Volume2.57M
52 Week high
$49.62
52 Week high$49.62
52 Week low
$31.90
52 Week low$31.90

Stock Snapshot

The current Exelixis(EXEL) stock price is $42.36, with a market capitalization of 11.17B. The stock trades at a price-to-earnings (P/E) ratio of 17.53.

During the trading session on 2025-11-15, Exelixis(EXEL) shares reached a daily high of $42.59 and a low of $39.50. At a current price of $42.36, the stock is +7.2% higher than the low and still -0.5% under the high.

Trading volume for Exelixis(EXEL) stock has reached 2.57M, versus its average volume of 3.18M.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $31.90.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $31.90.

EXEL News

Simply Wall St 9h
Will Strong Q3 Results and $750M Buyback Shift Exelixis' Outlook?

Exelixis reported strong third quarter results, raised its earnings guidance for 2025, and announced a new US$750 million share repurchase program, following a...

Will Strong Q3 Results and $750M Buyback Shift Exelixis' Outlook?

Analyst ratings

55%

of 20 ratings
Buy
55%
Hold
45%
Sell
0%

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.